Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs

Core Viewpoint - Nexalin Technology, Inc. has appointed Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs, bringing over 30 years of experience in the medical device industry to the company [1][3] Company Overview - Nexalin Technology designs and develops innovative neurostimulation products aimed at addressing the global mental health epidemic, utilizing bioelectronic medical technology to treat mental health issues [4] Leadership Appointment - Carolyn Shelton's extensive background includes leadership roles at Openwater Health, Advanced Sterilization Products, and Medtronic, where she successfully navigated complex regulatory landscapes and led clinical trials [2][3] - Shelton's experience includes filing for FDA Breakthrough designation and achieving compliance with the EU MDR, which will be crucial for Nexalin's future regulatory submissions [2][3] Strategic Importance - The appointment of Shelton is seen as a strategic addition to Nexalin's executive team, particularly as the company prepares for international rollout of its Deep Intracranial Frequency Stimulation (DIFS) technology and seeks future FDA Breakthrough Device designations [3] - Shelton expressed enthusiasm about joining Nexalin, highlighting the unmet need for effective, drug-free alternatives for treating mental health conditions [3]